Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
VIOME LIFE SCIENCES, INC. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, showing that the company's biological research is being examined in different technical categories. The prosecution involves distinct examiners, ensuring that each active case is subject to an independent review process by the patent office.
VANN-OJUEKAIYE, KENDRA RAYCHELL is the busiest examiner for the company, holding 1 pending office action. With a total of 2 pending office actions and distinct examiners, the workload is evenly divided, with the busiest examiner responsible for a portion of the cases. This arrangement across 2 distinct art units means the applicant must navigate the specific requirements of different examination environments simultaneously. The lack of concentration with a single examiner reduces the risk of a single point of failure for the portfolio.
For a practitioner, this spread within the Biotechnology & Pharmaceuticals sector requires a tailored approach for each application. The 1 pending office action under the busiest examiner must be managed alongside the other active matter, each requiring attention to different examiner preferences. Because the cases are in different art units, the legal team should prepare for varying interpretations of patentability standards. Success for VIOME LIFE SCIENCES, INC. depends on effectively addressing the unique technical challenges presented in each of the distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
| MCCORMACK, ERIN KATHLEEN | 1 | 7.9% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779364 | SAMPLE COLLECTION DEVICE WITH REAGENT | MCCORMACK, ERIN KATHLEEN | 331d overdue |
| 17915082 | DIAGNOSTIC FOR ORAL CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779364 | SAMPLE COLLECTION DEVICE WITH REAGENT | MCCORMACK, ERIN KATHLEEN | 331d overdue |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17915082 | DIAGNOSTIC FOR ORAL CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §101§103 | Final Rejection | — | Pending | Jun 20, 2023 |
| 17779364 | SAMPLE COLLECTION DEVICE WITH REAGENT | MCCORMACK, ERIN KATHLEEN | 3791 | §102§103§112 | Final Rejection | 331d overdue | Pending | May 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVIOME LIFE SCIENCES, INC. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kendra Raychell Vann-Ojuekaiye has the most, with 1 of VIOME LIFE SCIENCES, INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
